Summary
Global Markets Direct’s, ‘Down Syndrome - Pipeline Review, H2 2016’, provides an overview of the Down Syndrome pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Down Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Down Syndrome and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Down Syndrome
- The report reviews pipeline therapeutics for Down Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Down Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Down Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Down Syndrome
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Down Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Down Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AC Immune SA
Aelis Farma SAS
Cortice Biosciences, Inc.
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
NeuroNascent, Inc.
Transition Therapeutics Inc.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Down Syndrome Overview 7
Therapeutics Development 8
Pipeline Products for Down Syndrome - Overview 8
Pipeline Products for Down Syndrome - Comparative Analysis 9
Down Syndrome - Therapeutics under Development by Companies 10
Down Syndrome - Therapeutics under Investigation by Universities/Institutes 11
Down Syndrome - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Down Syndrome - Products under Development by Companies 15
Down Syndrome - Products under Investigation by Universities/Institutes 16
Down Syndrome - Companies Involved in Therapeutics Development 17
AC Immune SA 17
Aelis Farma SAS 18
Cortice Biosciences, Inc. 19
Eisai Co., Ltd. 20
F. Hoffmann-La Roche Ltd. 21
NeuroNascent, Inc. 22
Transition Therapeutics Inc. 23
Down Syndrome - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
ACI-24 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
ALZ-801 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
APH-1104 - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
basmisanil - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
D-217 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
donepezil hydrochloride - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
Dosmir - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
ELND-005 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
minocycline - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
NNI-351 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
NNI-362 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
Pentylenetetrazol - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecule to inhibit DYRK1A for CNS Diseases - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Small Molecules for Down Syndrome - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecules to Inhibit OLIG2 for Down Syndrome - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Stem Cell Therapy to Activate ZSCAN4 for Down Syndrome and Edwards Syndrome - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
xamoterol fumarate - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Down Syndrome - Discontinued Products 63
Down Syndrome - Product Development Milestones 64
Featured News & Press Releases 64
Apr 05, 2016: AC Immune Announces Publication of Ground-breaking Scientific Publication on anti-Abeta Vaccine in Preclinical Model of Down Syndrome 64
Feb 05, 2015: Neuronascent Announces Expanded Patent Coverage in Russia for Its Down Syndrome Therapeutics 65
Nov 20, 2014: Transition Therapeutics Announces Results from ELND005 Clinical Study in Adults with Down Syndrome 65
Apr 07, 2014: Transition Therapeutics Announces Development Update 65
Sep 04, 2013: Transition Therapeutics Announces Dosing of the First Patient in Phase 2a Study of ELND005 in Down Syndrome 67
Sep 03, 2013: Elan Announces Dosing of First Patient in Phase 2a Trial of ELND005 (Scyllo-inositol) in Down Syndrome 67
Feb 27, 2013: Roche Provides Update On Its Clinical Candidate For Down Syndrome 67
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 68
Disclaimer 69
List of Tables
Number of Products under Development for Down Syndrome, H2 2016 8
Number of Products under Development for Down Syndrome - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Development, H2 2016 13
Comparative Analysis by Unknown Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Down Syndrome - Pipeline by AC Immune SA, H2 2016 17
Down Syndrome - Pipeline by Aelis Farma SAS, H2 2016 18
Down Syndrome - Pipeline by Cortice Biosciences, Inc., H2 2016 19
Down Syndrome - Pipeline by Eisai Co., Ltd., H2 2016 20
Down Syndrome - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 21
Down Syndrome - Pipeline by NeuroNascent, Inc., H2 2016 22
Down Syndrome - Pipeline by Transition Therapeutics Inc., H2 2016 23
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Stage and Target, H2 2016 26
Number of Products by Stage and Mechanism of Action, H2 2016 28
Number of Products by Stage and Route of Administration, H2 2016 30
Number of Products by Stage and Molecule Type, H2 2016 32
Down Syndrome - Discontinued Products, H2 2016 63
List of Figures
Number of Products under Development for Down Syndrome, H2 2016 8
Number of Products under Development for Down Syndrome - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Comparative Analysis by Early Stage Products, H2 2016 13
Assessment by Monotherapy Products, H2 2016 24
Number of Products by Top 10 Targets, H2 2016 25
Number of Products by Stage and Top 10 Targets, H2 2016 25
Number of Products by Top 10 Mechanism of Actions, H2 2016 27
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 27
Number of Products by Routes of Administration, H2 2016 29
Number of Products by Stage and Routes of Administration, H2 2016 29
Number of Products by Molecule Types, H2 2016 31
Number of Products by Stage and Molecule Types, H2 2016 31
